The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients
IL-17A 在 VA 患者糖尿病视网膜病变发生和进展中的作用
基本信息
- 批准号:10657466
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressBackground Diabetic RetinopathyBiological AssayBlindnessBloodBlood VesselsBlood capillariesCancer PatientCaringCellsCentrifugationChronicClinical ResearchCollaborationsComplications of Diabetes MellitusDiabetes MellitusDiabetic RetinopathyDiabetic mouseDiseaseDrug resistanceEarly treatmentEnzyme-Linked Immunosorbent AssayExtravasationEyeFDA approvedFicollFundusGoalsHealthHealthcareIL17 geneImmune systemImpairmentIndividualInflammationInflammatoryInjuryInterleukinsMalignant NeoplasmsMediatingMicrovascular DysfunctionOperative Surgical ProceduresOxidative StressPathogenesisPathologicPatientsPharmaceutical PreparationsPlasmaPlayPopulationPrediabetes syndromeProductionProliferatingProteinsResistanceRetinaRetinal DiseasesRoleSeveritiesSourceSystemThickTight JunctionsTreatment FactorType 2 diabeticVascular Endothelial Growth FactorsVascular PermeabilitiesVascular ProliferationVeteransVisionVisualVitrectomyaging populationalternative treatmentcare burdencytokinedensitydiabeticimprovedintravitreal injectionmaculamacular edemamilitary veteranmouse modelneutrophilnew therapeutic targetnon-diabeticnovelnovel therapeuticsophthalmic examinationperipheral bloodproliferative diabetic retinopathyranibizumabresponders and non-respondersresponseretina blood vessel structureretinal angiogenesisscreeningtherapeutic target
项目摘要
Abstract
Currently, 9% of the US population is diabetic, and an additional 86 million are being treated for
pre-diabetes. Beyond this, one in every four Veteran receiving care from the VA is being treated
for diabetes and its many physical complications, with more than half suffering from diabetic
retinopathy. Making diabetic retinopathy a disease with a high healthcare burden in the Veteran
population. Diabetic retinopathy is a microvascular disease of the retina, and is the leading
cause of blindness in the working-age population worldwide. With such a significant health
impact, new therapeutics is required to stay abreast of the financial and physical threat posed
by this visual disease. One of the most promising sources of such a therapeutic target lies within
the immune system. The alteration of the immune system mediates much of the pathogenesis in
diabetic complications through protein cytokine production, with IL-17A being one of the most
prevalent cytokines involved in the onset and progression of diabetes. In our previous studies,
we discovered that diabetes induced IL-17A production, which enhanced retinal inflammation,
oxidative stress, vascular impairment, and the onset of non-proliferative diabetic retinopathy in
murine models of diabetes. In the current study we will examine if IL-17A plays the same
pathologic role in the progression of non-proliferative diabetic retinopathy, proliferative diabetic
retinopathy, and diabetic macular edema in our VA patients. Further, previous cancer studies
provide evidence that IL-17A induces anti-VEGF drug resistance. Here we will examine if IL-17A
plays the same role in patients that do not respond to anti-VEGF treatments for diabetic
retinopathy. Taken together, these studies will define the role of IL-17A in the onset and
progression of diabetic retinopathy, while potentially identifying a novel therapeutic for retinal
pathogenesis.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Patricia R Taylor其他文献
Patricia R Taylor的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Patricia R Taylor', 18)}}的其他基金
The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients
IL-17A 在 VA 患者糖尿病视网膜病变发生和进展中的作用
- 批准号:
10426051 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics
糖尿病视网膜病变治疗的免疫调节剂的鉴定
- 批准号:
10132337 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics
糖尿病视网膜病变治疗的免疫调节剂的鉴定
- 批准号:
10382423 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics
糖尿病视网膜病变治疗的免疫调节剂的鉴定
- 批准号:
10617636 - 财政年份:2020
- 资助金额:
-- - 项目类别:
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy
IL-17 中性粒细胞和淋巴细胞在糖尿病视网膜病变中的作用
- 批准号:
9137364 - 财政年份:2016
- 资助金额:
-- - 项目类别:
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy
IL-17 中性粒细胞和淋巴细胞在糖尿病视网膜病变中的作用
- 批准号:
9898287 - 财政年份:2016
- 资助金额:
-- - 项目类别:
相似海外基金
Do activated retinal microglia mediate neurotoxicity in background diabetic retinopathy?
激活的视网膜小胶质细胞是否介导背景糖尿病视网膜病变的神经毒性?
- 批准号:
nhmrc : 634469 - 财政年份:2010
- 资助金额:
-- - 项目类别:
NHMRC Project Grants
ELECTRORETINOGRAM IN BACKGROUND DIABETIC RETINOPATHY
背景糖尿病视网膜病变的视网膜电图
- 批准号:
2163311 - 财政年份:1991
- 资助金额:
-- - 项目类别: